Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has successfully completed its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient in its lead oncology candidate, ONC010. The program, conducted in collaboration with Dalton Pharma Services, establishes a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities, according to a company announcement.
The milestone strengthens the company’s chemistry, manufacturing, and controls (CMC) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. Onco-Innovations stated that the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
ONC010 is being developed as a potential treatment for solid tumors, building on patented technology for which Onco-Innovations holds an exclusive worldwide license. The company, based in Canada, focuses on cancer research and treatment, aiming to prevent and treat cancer through innovative solutions.
The completion of the reference standard program is a critical step in the drug development process, as it ensures that the active ingredient can be consistently identified and measured, which is essential for regulatory submissions and eventual clinical trials. With this achievement, Onco-Innovations is better positioned to meet the stringent requirements of health authorities as it moves ONC010 toward the clinic.
Investors and stakeholders can find the latest news and updates regarding Onco-Innovations at the company’s newsroom at https://ibn.fm/ONNVF.
This development underscores Onco-Innovations' commitment to advancing its pipeline and highlights the importance of robust CMC practices in oncology drug development. As the company continues to refine its manufacturing and quality control processes, the successful establishment of the reference standard marks a tangible step toward bringing ONC010 to patients in need.
